Robyn T Sussman Advances in Neuroblastoma Research Congress 2016

Abstracts this author is presenting:

• A CD56 (NCAM1) targeting antibody-drug conjugate is potently effective in preclinical models of high-risk neuroblastoma — Parallel 4 Novel Therapies and Immunotherapy
• CAMKV is a candidate immunotherapeutic target in MYCN-amplified neuroblastoma. — Poster Session 1 with wine & cheese